Johnson & Johnson (JNJ)

$203.90 +0.83 (0.41%)
Market Cap 489.26B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 19.51
Forward PE 18.64
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 13,189,000
Avg Vol 8,892,628
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 83%
Beta 0.38
Analysts Strong Sell
Price Target $203.50

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
LiquidThetaOptions
LiquidThetaOptions Nov. 22 at 6:47 PM
💎 LiquidTheta® Live Actionable Trade Asset: $JNJ Contracts: $JNJ December 18, 2026 $210 Calls Scale in: $13.24- $16.18 Scale out: $51.48-$88.26 Profit Potential : 163% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
TalkMarkets
TalkMarkets Nov. 22 at 5:21 PM
#2025 Might Feel Lost, But #NextYear Looks Brighter $TGT $WMT Also $IBM $JNJ $SPX https://talkmarkets.com/content/stocks--equities/2025-might-feel-lost-but-next-year-looks-brighter?post=539669&userid=123969
0 · Reply
stockanalysis_
stockanalysis_ Nov. 22 at 3:51 PM
Top-Rated Dividend Stocks: $JPM $XOM $JNJ $BAC $UNH Bookmark this page: https://stockanalysis.com/list/top-rated-dividend-stocks/?ref=saveontrading
0 · Reply
kg354
kg354 Nov. 22 at 2:47 PM
$GOOG $LLY $JNJ Great momentum quality stocks!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 22 at 1:07 PM
Enter: $JNJ Calls Strike Price: $210 Expiry Date: DEC 12 2025 Buy in Price: $1.45 - $1.97 Sell Price: $2.35 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 11:17 PM
Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $202.50 Put · NOV 28, 2025 Exp Entry Price: $2.03 - $2.20 Exit Price Target: $4.26 Profit Margin: +110% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
mdes
mdes Nov. 21 at 10:58 PM
$JNJ want to hold this for long term. However, chart today shows gravestone doji a reversal of recent bull run.. not sure what to do.. please advise
1 · Reply
Ro_Patel
Ro_Patel Nov. 21 at 8:41 PM
US HHS Secretary RFK Jr told NYT he instructed the CDC to abandon its position that vaccines cause autism --- No word on circumcisions - I'm still wondering if I have autism or not!!! $PFE $MRNA $BNTX $JNJ $XLV
1 · Reply
Iightning
Iightning Nov. 21 at 8:21 PM
1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $200 Call | Enter: $2.82 Exit: $4.00 | Profit: 41.81% ROI | https://1ightning.com
0 · Reply
smartkarma
smartkarma Nov. 21 at 6:03 PM
$JNJ | Johnson & Johnson Buys Halda: The Cancer Deal Wall Street Didn’t See Coming! "Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company. The..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/johnson-johnson-buys-halda-the-cancer-deal-wall-street-didn-t-see-coming
0 · Reply
Latest News on JNJ
Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Nov 18, 2025, 4:21 PM EST - 3 days ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN LLY MDT MRK NVO OLMA PFE

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 4 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK LLY

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Nov 17, 2025, 6:07 PM EST - 4 days ago

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 1:17 PM EST - 5 days ago

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 5 days ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 5 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

Nov 17, 2025, 8:07 AM EST - 5 days ago

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 8:05 AM EST - 5 days ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Nov 17, 2025, 8:00 AM EST - 5 days ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 8 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN LLY MRK NVO PFE XLV

Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 8 days ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 1:41 PM EST - 11 days ago

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 11, 2025, 12:51 PM EST - 11 days ago

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Nov 10, 2025, 6:26 AM EST - 12 days ago

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Nov 7, 2025, 12:57 PM EST - 15 days ago

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 15 days ago

Johnson & Johnson: Dividends Don't Lie

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Nov 6, 2025, 5:07 PM EST - 15 days ago

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 16 days ago

Cramer's Mad Dash: Johnson & Johnson

US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:34 AM EST - 16 days ago

US FDA expands use of J&J's Caplyta as add-on depression drug

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Nov 6, 2025, 7:30 AM EST - 16 days ago

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Nov 5, 2025, 4:50 PM EST - 16 days ago

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 21 days ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Oct 29, 2025, 8:05 AM EDT - 24 days ago

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 24 days ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX

Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson

Oct 28, 2025, 6:15 PM EDT - 24 days ago

Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson

J&J Stock Can Fall

Oct 28, 2025, 9:25 AM EDT - 25 days ago

J&J Stock Can Fall

Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks

Oct 28, 2025, 9:13 AM EDT - 25 days ago

Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks

KVUE

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

Oct 27, 2025, 8:00 AM EDT - 26 days ago

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Oct 27, 2025, 7:30 AM EDT - 26 days ago

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

Oct 27, 2025, 7:30 AM EDT - 26 days ago

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

Oct 24, 2025, 6:32 PM EDT - 4 weeks ago

Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

Oct 24, 2025, 8:00 AM EDT - 4 weeks ago

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

Oct 24, 2025, 4:30 AM EDT - 4 weeks ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IQV IVZ LRCX

These low-risk stocks could be a profitable answer to this volatile earnings season

Oct 23, 2025, 10:52 AM EDT - 4 weeks ago

These low-risk stocks could be a profitable answer to this volatile earnings season

AMGN BMY CVS GD GIS HQY HRL

Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference

Oct 22, 2025, 4:36 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference

Johnson & Johnson Stock To $134?

Oct 22, 2025, 2:00 PM EDT - 4 weeks ago

Johnson & Johnson Stock To $134?

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Oct 19, 2025, 10:30 AM EDT - 4 weeks ago

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

Oct 16, 2025, 8:00 AM EDT - 5 weeks ago

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

J&J faces first UK lawsuits alleging its baby powder caused cancer

Oct 15, 2025, 7:03 PM EDT - 5 weeks ago

J&J faces first UK lawsuits alleging its baby powder caused cancer

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Oct 15, 2025, 2:04 PM EDT - 5 weeks ago

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Oct 15, 2025, 1:56 PM EDT - 5 weeks ago

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business

Oct 15, 2025, 7:51 AM EDT - 5 weeks ago

Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business

'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations

Oct 14, 2025, 7:30 PM EDT - 5 weeks ago

'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 12:36 PM EDT - 5 weeks ago

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides

Oct 14, 2025, 10:01 AM EDT - 5 weeks ago

Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides

C DPZ

Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again

Oct 14, 2025, 8:58 AM EDT - 5 weeks ago

Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again

Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast

Oct 14, 2025, 8:56 AM EDT - 5 weeks ago

Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Oct 14, 2025, 8:51 AM EDT - 5 weeks ago

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff

Oct 14, 2025, 7:44 AM EDT - 5 weeks ago

Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff

J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth

Oct 14, 2025, 7:33 AM EDT - 5 weeks ago

J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth

LiquidThetaOptions
LiquidThetaOptions Nov. 22 at 6:47 PM
💎 LiquidTheta® Live Actionable Trade Asset: $JNJ Contracts: $JNJ December 18, 2026 $210 Calls Scale in: $13.24- $16.18 Scale out: $51.48-$88.26 Profit Potential : 163% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
TalkMarkets
TalkMarkets Nov. 22 at 5:21 PM
#2025 Might Feel Lost, But #NextYear Looks Brighter $TGT $WMT Also $IBM $JNJ $SPX https://talkmarkets.com/content/stocks--equities/2025-might-feel-lost-but-next-year-looks-brighter?post=539669&userid=123969
0 · Reply
stockanalysis_
stockanalysis_ Nov. 22 at 3:51 PM
Top-Rated Dividend Stocks: $JPM $XOM $JNJ $BAC $UNH Bookmark this page: https://stockanalysis.com/list/top-rated-dividend-stocks/?ref=saveontrading
0 · Reply
kg354
kg354 Nov. 22 at 2:47 PM
$GOOG $LLY $JNJ Great momentum quality stocks!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 22 at 1:07 PM
Enter: $JNJ Calls Strike Price: $210 Expiry Date: DEC 12 2025 Buy in Price: $1.45 - $1.97 Sell Price: $2.35 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 11:17 PM
Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $202.50 Put · NOV 28, 2025 Exp Entry Price: $2.03 - $2.20 Exit Price Target: $4.26 Profit Margin: +110% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
mdes
mdes Nov. 21 at 10:58 PM
$JNJ want to hold this for long term. However, chart today shows gravestone doji a reversal of recent bull run.. not sure what to do.. please advise
1 · Reply
Ro_Patel
Ro_Patel Nov. 21 at 8:41 PM
US HHS Secretary RFK Jr told NYT he instructed the CDC to abandon its position that vaccines cause autism --- No word on circumcisions - I'm still wondering if I have autism or not!!! $PFE $MRNA $BNTX $JNJ $XLV
1 · Reply
Iightning
Iightning Nov. 21 at 8:21 PM
1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $200 Call | Enter: $2.82 Exit: $4.00 | Profit: 41.81% ROI | https://1ightning.com
0 · Reply
smartkarma
smartkarma Nov. 21 at 6:03 PM
$JNJ | Johnson & Johnson Buys Halda: The Cancer Deal Wall Street Didn’t See Coming! "Johnson & Johnson's first quarter 2025 results present a multifaceted picture of a robust yet intricately challenged healthcare company. The..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/johnson-johnson-buys-halda-the-cancer-deal-wall-street-didn-t-see-coming
0 · Reply
RunnerSignals
RunnerSignals Nov. 21 at 5:41 PM
52-Week Highs $NVRI $LLY $JNJ $ROST $TXG hitting fresh highs today. check the full movers list https://stocksrunner.com/news/2025-11-21-52-week-highs-breakout-stocks
0 · Reply
GettnFibbywIT
GettnFibbywIT Nov. 21 at 5:29 PM
$JNJ $XLV $XPH
0 · Reply
peloswing
peloswing Nov. 21 at 3:04 PM
$JNJ Daily Chart 💊 Double 🔝 on RSI & Top of Channel 👀
0 · Reply
VisualTrader
VisualTrader Nov. 21 at 8:28 AM
$JNJ uncharted territory.
0 · Reply
Jwil727
Jwil727 Nov. 21 at 7:25 AM
$DDS If you like dividends you might want to check out Dillards. They just announced a special dividend of $30 a share. 💰💰 $PEP $JNJ $TGT $PFE
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 11:28 PM
Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $202.50 Put · NOV 28, 2025 Exp Entry Price: $1.97 - $2.01 Exit Price Target: $4.08 Profit Margin: +107% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
ChillTrader
ChillTrader Nov. 20 at 11:24 PM
$JNJ TP for tomorrow
0 · Reply
TalkMarkets
TalkMarkets Nov. 20 at 11:17 PM
#Biotech Deals Propel Sector To New 2025 Highs $AZN $JNJ $MRK $RHHBY $IBB https://talkmarkets.com/content/stocks--equities/biotech-deals-propel-sector-to-new-2025-highs?post=539241
0 · Reply
Iightning
Iightning Nov. 20 at 11:10 PM
1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $200 Call | Enter: $2.82 Exit: $4.00 | Profit: 41.81% ROI | https://1ightning.com
0 · Reply
theoptionscoach
theoptionscoach Nov. 20 at 9:53 PM
$DJI $SPY $QQQ $WMT $JNJ Hello from theoptionscoach.net https://theoptionscoach.net/p/big-red-day
0 · Reply
Peaceouty
Peaceouty Nov. 20 at 8:53 PM
$CANF $JNJ $QQQ $SPY $XBI No worries ✌🏻
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 20 at 8:45 PM
Enter: $JNJ Calls Strike Price: $205 Expiry Date: DEC 12 2025 Buy in Price: $2.77 - $2.78 Sell Price: $5.90 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply